-
1
-
-
22044442973
-
Tyrosine kinases as targets for cancer therapy
-
Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005;353:172-87.
-
(2005)
N Engl J Med
, vol.353
, pp. 172-187
-
-
Krause, D.S.1
Van Etten, R.A.2
-
2
-
-
15544381413
-
Receptor tyrosine kinases and anticancer therapy
-
Medinger M, Drevs J. Receptor tyrosine kinases and anticancer therapy. Curr Pharm Des 2005;11:1139-49.
-
(2005)
Curr Pharm Des
, vol.11
, pp. 1139-1149
-
-
Medinger, M.1
Drevs, J.2
-
3
-
-
0034722889
-
The EGF receptor family as targets for cancer therapy
-
Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000;19:6550-65.
-
(2000)
Oncogene
, vol.19
, pp. 6550-6565
-
-
Mendelsohn, J.1
Baselga, J.2
-
4
-
-
14644445166
-
Epidermal growth factor receptor signaling in colorectal cancer: Preclinical data and therapeutic perspectives
-
Spano JP, Fagard R, Soria JC, et al. Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives. Ann Oncol 2005;16:189-94.
-
(2005)
Ann Oncol
, vol.16
, pp. 189-194
-
-
Spano, J.P.1
Fagard, R.2
Soria, J.C.3
-
5
-
-
0028168569
-
Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity
-
Guy PM, Platko JV, Cantley LC, Cerione RA, Carraway KL III. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci U S A 1994;91:8132-6.
-
(1994)
Proc Natl Acad Sci U S A
, vol.91
, pp. 8132-8136
-
-
Guy, P.M.1
Platko, J.V.2
Cantley, L.C.3
Cerione, R.A.4
Carraway III, K.L.5
-
6
-
-
0032529048
-
Signal transduction by epidermal growth factor and heregulin via the kinase-deficient ErbB3 protein
-
Kim HH, Vijapurkar U, Hellyer NJ, Bravo D, Koland JG. Signal transduction by epidermal growth factor and heregulin via the kinase-deficient ErbB3 protein. Biochem J 1998;334:189-95.
-
(1998)
Biochem J
, vol.334
, pp. 189-195
-
-
Kim, H.H.1
Vijapurkar, U.2
Hellyer, N.J.3
Bravo, D.4
Koland, J.G.5
-
7
-
-
0036479747
-
Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival
-
Grant S, Qiao L, Dent P. Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival. Front Biosci 2002;7:d376-89.
-
(2002)
Front Biosci
, vol.7
-
-
Grant, S.1
Qiao, L.2
Dent, P.3
-
8
-
-
0034799139
-
A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor
-
Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7:2958-70.
-
(2001)
Clin Cancer Res
, vol.7
, pp. 2958-2970
-
-
Ciardiello, F.1
Tortora, G.2
-
9
-
-
2342471392
-
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
-
Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
-
(2004)
N Engl J Med
, vol.350
, pp. 2129-2139
-
-
Lynch, T.J.1
Bell, D.W.2
Sordella, R.3
-
10
-
-
2342624080
-
EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy
-
Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
-
(2004)
Science
, vol.304
, pp. 1497-1500
-
-
Paez, J.G.1
Janne, P.A.2
Lee, J.C.3
-
11
-
-
0034954124
-
The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy
-
Pedersen MW, Meltorn M, Damstrup L, Poulsen HS. The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. Ann Oncol 2001;12:745-60.
-
(2001)
Ann Oncol
, vol.12
, pp. 745-760
-
-
Pedersen, M.W.1
Meltorn, M.2
Damstrup, L.3
Poulsen, H.S.4
-
12
-
-
0028863853
-
Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene
-
Batra SK, Castelino-Prabhu S, Wikstrand CJ, et al. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ 1995;6:1251-9.
-
(1995)
Cell Growth Differ
, vol.6
, pp. 1251-1259
-
-
Batra, S.K.1
Castelino-Prabhu, S.2
Wikstrand, C.J.3
-
13
-
-
19944427851
-
Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer
-
Amann J, Kalyankrishna S, Massion PP, et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 2005;65:226-35.
-
(2005)
Cancer Res
, vol.65
, pp. 226-235
-
-
Amann, J.1
Kalyankrishna, S.2
Massion, P.P.3
-
14
-
-
18244371651
-
-
Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoSMed 2005;2:e73.
-
Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoSMed 2005;2:e73.
-
-
-
-
15
-
-
14644440555
-
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis
-
Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011-27.
-
(2005)
J Clin Oncol
, vol.23
, pp. 1011-1027
-
-
Hicklin, D.J.1
Ellis, L.M.2
-
17
-
-
4644290521
-
Eph receptor tyrosine kinases in tumor and tumor microenvironment
-
Brantley-Sieders D, Parker M, Chen J. Eph receptor tyrosine kinases in tumor and tumor microenvironment. Curr Pharm Des 2004;10:3431-42.
-
(2004)
Curr Pharm Des
, vol.10
, pp. 3431-3442
-
-
Brantley-Sieders, D.1
Parker, M.2
Chen, J.3
-
18
-
-
2442421790
-
Effects of overexpression of ephrin-B2 on tumour growth in human colorectal cancer
-
Liu W, Jung YD, Ahmad SA, et al. Effects of overexpression of ephrin-B2 on tumour growth in human colorectal cancer. Br J Cancer 2004;90:1620-6.
-
(2004)
Br J Cancer
, vol.90
, pp. 1620-1626
-
-
Liu, W.1
Jung, Y.D.2
Ahmad, S.A.3
-
19
-
-
0842282623
-
Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist
-
Dobrzanski P, Hunter K, Jones-Bolin S, et al. Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist. Cancer Res 2004;64:910-9.
-
(2004)
Cancer Res
, vol.64
, pp. 910-919
-
-
Dobrzanski, P.1
Hunter, K.2
Jones-Bolin, S.3
-
20
-
-
0037093097
-
Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior
-
Carles-Kinch K, Kilpatrick KE, Stewart JC, Kinch MS. Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. Cancer Res 2002;62:2840-7.
-
(2002)
Cancer Res
, vol.62
, pp. 2840-2847
-
-
Carles-Kinch, K.1
Kilpatrick, K.E.2
Stewart, J.C.3
Kinch, M.S.4
-
21
-
-
21144433227
-
EphB4 expression and biological significance in prostate cancer
-
Xia G, Kumar SR, Masood R, et al. EphB4 expression and biological significance in prostate cancer. Cancer Res 2005;65:4623-32.
-
(2005)
Cancer Res
, vol.65
, pp. 4623-4632
-
-
Xia, G.1
Kumar, S.R.2
Masood, R.3
-
22
-
-
0036785161
-
Diverse roles for the Eph family of receptor tyrosine kinases in carcinogenesis
-
Nakamoto M, Bergemann AD. Diverse roles for the Eph family of receptor tyrosine kinases in carcinogenesis. Microsc Res Tech 2002;59:58-67.
-
(2002)
Microsc Res Tech
, vol.59
, pp. 58-67
-
-
Nakamoto, M.1
Bergemann, A.D.2
-
23
-
-
0034693857
-
Eph receptors and ephrin ligands: Embryogenesis to tumorigenesis
-
Dodelet VC, Pasquale EB. Eph receptors and ephrin ligands: embryogenesis to tumorigenesis. Oncogene 2000;19:5614-9.
-
(2000)
Oncogene
, vol.19
, pp. 5614-5619
-
-
Dodelet, V.C.1
Pasquale, E.B.2
-
24
-
-
20444431504
-
The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade
-
Sini P, Wyder L, Schnell C, et al. The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade. Clin Cancer Res 2005;15:4521-32.
-
(2005)
Clin Cancer Res
, vol.15
, pp. 4521-4532
-
-
Sini, P.1
Wyder, L.2
Schnell, C.3
-
25
-
-
18844365440
-
Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors
-
Chan CT, Metz MZ, Kane SE. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors. Breast Cancer Res Treat 2005;91:187-201.
-
(2005)
Breast Cancer Res Treat
, vol.91
, pp. 187-201
-
-
Chan, C.T.1
Metz, M.Z.2
Kane, S.E.3
-
26
-
-
33645735004
-
Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia
-
Franco M, Man S, Chen L, et al. Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. Cancer Res 2006;66:3639-48.
-
(2006)
Cancer Res
, vol.66
, pp. 3639-3648
-
-
Franco, M.1
Man, S.2
Chen, L.3
-
27
-
-
7044234484
-
Different signalling pathways regulate VEGF and IL-8 expression in breast cancer: Implications for therapy
-
Chelouche-Lev D, Miller CP, Tellez C, et al. Different signalling pathways regulate VEGF and IL-8 expression in breast cancer: implications for therapy. Eur J Cancer 2004;40:2509-18.
-
(2004)
Eur J Cancer
, vol.40
, pp. 2509-2518
-
-
Chelouche-Lev, D.1
Miller, C.P.2
Tellez, C.3
-
28
-
-
0032016685
-
EGFR antisense RNA blocks expression of the epidermal growth factor receptor and partially reverse the malignant phenotype of human breast cancer MDA-MB-231 cells
-
Fan W H, Lu YL, Deng F, et al. EGFR antisense RNA blocks expression of the epidermal growth factor receptor and partially reverse the malignant phenotype of human breast cancer MDA-MB-231 cells. Cell Res 1998;8:63-71.
-
(1998)
Cell Res
, vol.8
, pp. 63-71
-
-
Fan, W.H.1
Lu, Y.L.2
Deng, F.3
-
29
-
-
34250761075
-
Receptor-type kinase modulators and methods of use
-
United States patent WO2004006846, Jan 22
-
Rice KD, Anand NK, Bussenius J, et al. Receptor-type kinase modulators and methods of use. United States patent WO2004006846. 2004 Jan 22.
-
(2004)
-
-
Rice, K.D.1
Anand, N.K.2
Bussenius, J.3
-
30
-
-
0035939330
-
Studies leading to the identification of ZD1839 (IRESSA): An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer
-
Barker AJ, Gibson KH, Grundy W, et al. Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 2001;11:1911-4.
-
(2001)
Bioorg Med Chem Lett
, vol.11
, pp. 1911-1914
-
-
Barker, A.J.1
Gibson, K.H.2
Grundy, W.3
-
31
-
-
34250715588
-
Preparation of
-
N-phenylquinazoline-4-amines as neoplasm inhibitors. United States patent WO9630347. 1996 Oct. 03
-
Schnur RC, Arnold LD. Preparation of N-phenylquinazoline-4-amines as neoplasm inhibitors. United States patent WO9630347. 1996 Oct. 03.
-
-
-
Schnur, R.C.1
Arnold, L.D.2
-
32
-
-
0026351375
-
Activation of the autocrine transforming growth factor a pathway in human squamous carcinoma cells
-
Reiss M, Stash EB, Vellucci VF, Zhou ZL. Activation of the autocrine transforming growth factor a pathway in human squamous carcinoma cells. Cancer Res 1991;51:6254-62.
-
(1991)
Cancer Res
, vol.51
, pp. 6254-6262
-
-
Reiss, M.1
Stash, E.B.2
Vellucci, V.F.3
Zhou, Z.L.4
-
33
-
-
0034234854
-
Tumor inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2
-
Klapper LN, Waterman H, Sela M, Yarden Y. Tumor inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res 2000;60:3384-8.
-
(2000)
Cancer Res
, vol.60
, pp. 3384-3388
-
-
Klapper, L.N.1
Waterman, H.2
Sela, M.3
Yarden, Y.4
-
34
-
-
20844460619
-
A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors
-
Chen LL, Trent JC, Wu EF, et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 2004;64:5913-9.
-
(2004)
Cancer Res
, vol.64
, pp. 5913-5919
-
-
Chen, L.L.1
Trent, J.C.2
Wu, E.F.3
-
35
-
-
0141599428
-
Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor
-
Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 2002;277:46265-72.
-
(2002)
J Biol Chem
, vol.277
, pp. 46265-46272
-
-
Stamos, J.1
Sliwkowski, M.X.2
Eigenbrot, C.3
-
36
-
-
0035800507
-
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
-
Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80.
-
(2001)
Science
, vol.293
, pp. 876-880
-
-
Gorre, M.E.1
Mohammed, M.2
Ellwood, K.3
-
37
-
-
3142676436
-
Overriding imatinib resistance with a novel ABL kinase inhibitor
-
Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399-401.
-
(2004)
Science
, vol.305
, pp. 399-401
-
-
Shah, N.P.1
Tran, C.2
Lee, F.Y.3
-
38
-
-
23844444080
-
An alternative inhibitor overcomes resistance caused by amutation of the epidermal growth factor receptor
-
Kobayashi S, Ji H, Yuza Y, et al. An alternative inhibitor overcomes resistance caused by amutation of the epidermal growth factor receptor. Cancer Res 2005;65:7096-101.
-
(2005)
Cancer Res
, vol.65
, pp. 7096-7101
-
-
Kobayashi, S.1
Ji, H.2
Yuza, Y.3
-
39
-
-
21144439000
-
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
-
Kwak EL, Sordella R, Bell DW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A 2005;102:7665-70.
-
(2005)
Proc Natl Acad Sci U S A
, vol.102
, pp. 7665-7670
-
-
Kwak, E.L.1
Sordella, R.2
Bell, D.W.3
|